28/08/2025
Living with lung cancer due to EGFR exon 20 insertion mutation?
Standard EGFR inhibitors may not always work โ but thereโs hope! Mobocertinib is designed to target this rare mutation in NSCLC, giving patients another line of therapy when options are limited. ๐
๐ Why it matters:
โ๏ธ Effective for mutation-positive lung cancer
โ๏ธ Expands treatment possibilities where others fail
โ๏ธ Awaiting launch in India โ a breakthrough in precision oncology
โ ๏ธ Like any treatment, it may cause side effects such as diarrhea, rash, or QT prolongation. Always consult a specialist before starting therapy.
Book an appointment:
Dr. Abhishek Raj
๐ MBBS, MD, DM (AIIMS)
๐ฅ Senior Consultant and Unit Head
๐ฌ Department of Medical Oncology, Hematology, and BMT
๐ Sarvodaya Hospital, Sector 8, Faridabad, Haryana
๐Contact: +91 9319913 575
๐ฉEmail: drabhishekonco@gmail.com
๐https://www.drabhishekraj.com
--------------------------------------------------
, leading in , patients can access through and . At , every step of focuses on better outcomes. Stay updated with , explore , and spread . Choose expert-led with trust and compassion.